Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Chimerix Inc. Stories

2013-03-28 08:27:52

- CMX001 data will also be presented in a poster session RESEARCH TRIANGLE PARK, N.C., March 28, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced presentations related to the use of its broad spectrum antiviral compound CMX001 at the European Group for Blood and Marrow Transplantation's (EBMT) Annual Meeting being held April 7-10, 2013 in London, United Kingdom. EBMT is a...

2013-03-14 08:28:24

RESEARCH TRIANGLE PARK, N.C., March 14, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that Michael D. Rogers, Ph.D., has joined the company as Chief Development Officer. Dr. Rogers will be responsible for overseeing chemistry, manufacturing, toxicology and project management as well as the advancement of compounds from the Chimerix Chemical Library. "We are extremely pleased to have...

2013-03-08 16:22:38

RESEARCH TRIANGLE PARK, N.C., March 8, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined. Morgan Stanley and...

2013-02-20 08:27:50

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Ernest Mario, Ph.D., as Chairman of its Board of Directors. "Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms. His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through Phase 3...

2013-02-19 08:31:46

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the BMT Tandem Meetings supporting the broad spectrum antiviral activity and emerging safety profile of CMX001. CMX001 is an oral nucleotide lipid-conjugate anticipated to start a Phase 3 study later this year. "These findings demonstrate CMX001's potential to be a safe and...

2013-02-04 08:25:18

RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing antivirals in areas of high unmet medical need, today announced that three abstracts related to the broad-spectrum antiviral compound CMX001 will be presented at the BMT Tandem Meetings being held February 13-17 in Salt Lake City. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the...

2012-11-26 08:23:53

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA. His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10 Project to...

2012-11-12 08:28:30

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Michelle Berrey, MD, MPH, has joined the company as Chief Medical Officer. "We are delighted to have Michelle join our leadership team. Dr. Berrey is a seasoned drug developer who has established a strong track record in antivirals, in particular with nucleotide analogs. She joins Chimerix at an important time for the...

2012-11-12 08:26:59

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced presentations at two upcoming investor conferences in New York. Both presentations will include an update on the Company's clinical pipeline, including its lead development compound, CMX001. Kenneth I. Moch, President & CEO, will present at the Lazard Capital Market 9th Annual Healthcare Conference on Wednesday, November...

2012-09-21 06:27:01

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced data highlighting the significant morbidity and resource utilization associated with the current standard of care for the management of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients. This analysis, entitled "Preemptive Therapy (PrT) for Cytomegalovirus (CMV) Post-hematopoietic Cell...